Akari Therapeutics

AKTX · NASDAQ

$9.29−$0.60 (−6.07%)TodayMarket closed · Oct 20, 6:16 PM ET

Prev close $9.89

Latest news

Press releaseOct 15, 9:20 AM ETGlobe Newswire
Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner
Press releaseOct 13, 9:01 AM ETGlobe Newswire
Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering
Press releaseOct 1, 8:25 AM ETGlobe Newswire
Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers
NewsSep 15, 8:05 AM ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Press releaseSep 8, 9:15 AM ETGlobe Newswire
Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums
Press releaseAug 27, 9:01 AM ETGlobe Newswire
Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
NewsAug 26, 1:06 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsAug 18, 11:37 AM ETVandana Singh
Akari Targets Mid-2027 for Human Trial of Differentiated Cancer Therapy
Press releaseAug 18, 8:53 AM ETGlobe Newswire
Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy
Press releaseAug 13, 4:15 PM ETGlobe Newswire
Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
Press releaseAug 4, 8:50 AM ETGlobe Newswire
Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation
Press releaseJul 22, 8:40 AM ETGlobe Newswire
Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity
Press releaseJul 21, 7:05 AM ETGlobe Newswire
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
NewsMay 22, 5:05 PM ET
12 Health Care Stocks Moving In Friday's After-Market Session
NewsMay 22, 1:04 PM ETAvi Kapoor
Crude Oil Edges Higher; US Consumer Sentiment Falls In May
NewsMay 22, 11:17 AM ETEvette Mitkov
Akari Therapeutics Stock Jumps On Promising Preclinical Data
NewsMay 22, 9:48 AM ETAvi Kapoor
Dow Jumps 250 Points; BJ's Wholesale Shares Fall After Q1 Results
NewsMay 21, 5:06 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
NewsMay 12, 5:06 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
NewsMay 12, 1:06 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
NewsMay 12, 8:06 AM ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
NewsMay 1, 8:05 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
NewsMar 25, 8:05 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NewsMar 19, 1:05 PM ET
12 Health Care Stocks Moving In Thursday's Intraday Session
NewsMar 18, 1:06 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsMar 18, 8:05 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NewsMar 17, 5:12 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
NewsMar 16, 5:05 PM ET
12 Health Care Stocks Moving In Monday's After-Market Session
NewsFeb 25, 7:05 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NewsDec 31, 6:14 AM ETAvi Kapoor
Why Vanda Pharmaceuticals Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
NewsDec 2, 12:05 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
NewsNov 5, 7:05 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NewsNov 4, 4:06 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
Press releaseFeb 3, 8:00 AM ETGlobe Newswire
Akari Therapeutics Joins Webull Corporate Connect Service Platform
Press releaseNov 8, 8:00 AM ETGlobe Newswire
Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger
Press releaseOct 15, 8:00 AM ETGlobe Newswire
Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger
Press releaseSep 17, 8:00 AM ETGlobe Newswire
Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner

Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering

Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums

Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference

12 Health Care Stocks Moving In Wednesday's Intraday Session

Akari Targets Mid-2027 for Human Trial of Differentiated Cancer Therapy

Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy

Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform

Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation

Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity

Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics

12 Health Care Stocks Moving In Friday's After-Market Session

Crude Oil Edges Higher; US Consumer Sentiment Falls In May

Akari Therapeutics Stock Jumps On Promising Preclinical Data

Dow Jumps 250 Points; BJ's Wholesale Shares Fall After Q1 Results

12 Health Care Stocks Moving In Thursday's After-Market Session

12 Health Care Stocks Moving In Tuesday's After-Market Session

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

12 Health Care Stocks Moving In Friday's Pre-Market Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

12 Health Care Stocks Moving In Thursday's Intraday Session

12 Health Care Stocks Moving In Wednesday's Intraday Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

12 Health Care Stocks Moving In Tuesday's After-Market Session

12 Health Care Stocks Moving In Monday's After-Market Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Why Vanda Pharmaceuticals Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

12 Health Care Stocks Moving In Tuesday's After-Market Session

Akari Therapeutics Joins Webull Corporate Connect Service Platform

Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger

Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger

Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics